FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2102392020> ?p ?o ?g. }

• W2102392020 endingPage "4938" @default.
• W2102392020 startingPage "4929" @default.
• W2102392020 abstract "Abstract Breast cancer metastasis to the bone occurs frequently, causing numerous complications including severe pain, fracture, hypercalcemia, and paralysis. Despite its prevalence and severity, few effective therapies exist. To address this, we examined whether the heat shock protein 90 (Hsp90) inhibitor, 17-allylamino-17-demethoxygeldanamycin (17-AAG), would be efficacious in inhibiting breast cancer metastasis to bone. Utilizing the human breast cancer subline, MDA-MB-231SA, previously in vivo selected for its enhanced ability to generate osteolytic bone lesions, we determined that 17-AAG potently inhibited its in vitro proliferation and migration. Moreover, 17-AAG significantly reduced MDA-MB-231SA tumor growth in the mammary-fat pad of nude mice. Despite these findings, 17-AAG enhanced the incidence of bone metastasis and osteolytic lesions following intracardiac inoculation in the nude mouse. Consistent with these findings, 17-AAG enhanced osteoclast formation 2- to 4-fold in mouse bone marrow/osteoblast cocultures, receptor activator of nuclear factor κB ligand (RANKL)–stimulated bone marrow, and RAW264.7 cell models of in vitro osteoclastogenesis. Moreover, the drug enhanced osteoclastogenesis in human cord blood progenitor cells, demonstrating that its effects were not limited to mouse models. In addition to 17-AAG, other Hsp90 inhibitors, such as radicicol and herbimycin A, also enhanced osteoclastogenesis. A pro-osteolytic action of 17-AAG independent of tumor presence was also determined in vivo, in which 17-AAG–treated tumor-naïve mice had reduced trabecular bone volume with an associated increase in osteoclast number. Thus, HSP90 inhibitors can stimulate osteoclast formation, which may underlie the increased incidence of osteolysis and skeletal tumor incidence caused by 17-AAG in vivo. These data suggest an important contraindication to the Hsp90 targeted cancer therapy currently undergoing clinical trial." @default.
• W2102392020 created "2016-06-24" @default.
• W2102392020 creator A5020653419 @default.
• W2102392020 creator A5024174638 @default.
• W2102392020 creator A5025585163 @default.
• W2102392020 creator A5029344208 @default.
• W2102392020 creator A5049570974 @default.
• W2102392020 creator A5051414786 @default.
• W2102392020 creator A5052081598 @default.
• W2102392020 creator A5071250790 @default.
• W2102392020 creator A5076700157 @default.
• W2102392020 creator A5082442667 @default.
• W2102392020 creator A5089405869 @default.
• W2102392020 date "2005-06-01" @default.
• W2102392020 modified "2023-10-01" @default.
• W2102392020 title "The Heat Shock Protein 90 Inhibitor, 17-Allylamino-17-demethoxygeldanamycin, Enhances Osteoclast Formation and Potentiates Bone Metastasis of a Human Breast Cancer Cell Line" @default.
• W2102392020 cites W1656339735 @default.
• W2102392020 cites W166215499 @default.
• W2102392020 cites W1909936605 @default.
• W2102392020 cites W1970392870 @default.
• W2102392020 cites W1979606076 @default.
• W2102392020 cites W1986471913 @default.
• W2102392020 cites W1988692190 @default.
• W2102392020 cites W1992473351 @default.
• W2102392020 cites W1993733425 @default.
• W2102392020 cites W2001215449 @default.
• W2102392020 cites W2009899654 @default.
• W2102392020 cites W2021534705 @default.
• W2102392020 cites W2023814104 @default.
• W2102392020 cites W2026987067 @default.
• W2102392020 cites W2033394124 @default.
• W2102392020 cites W2041216347 @default.
• W2102392020 cites W2042774871 @default.
• W2102392020 cites W2053926227 @default.
• W2102392020 cites W2059387208 @default.
• W2102392020 cites W2065784567 @default.
• W2102392020 cites W2067494371 @default.
• W2102392020 cites W2068948933 @default.
• W2102392020 cites W2075194293 @default.
• W2102392020 cites W2083637184 @default.
• W2102392020 cites W2085103893 @default.
• W2102392020 cites W2087324367 @default.
• W2102392020 cites W2102969047 @default.
• W2102392020 cites W2106766464 @default.
• W2102392020 cites W2109608328 @default.
• W2102392020 cites W2109689528 @default.
• W2102392020 cites W2111187586 @default.
• W2102392020 cites W2112945336 @default.
• W2102392020 cites W2113184090 @default.
• W2102392020 cites W2119263434 @default.
• W2102392020 cites W2122560580 @default.
• W2102392020 cites W2123056940 @default.
• W2102392020 cites W2133318825 @default.
• W2102392020 cites W2144332765 @default.
• W2102392020 cites W2146222370 @default.
• W2102392020 cites W2149683780 @default.
• W2102392020 cites W2152030479 @default.
• W2102392020 cites W2162107265 @default.
• W2102392020 cites W2175029576 @default.
• W2102392020 cites W4255941290 @default.
• W2102392020 cites W4376848667 @default.
• W2102392020 doi "https://doi.org/10.1158/0008-5472.can-04-4458" @default.
• W2102392020 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15930315" @default.
• W2102392020 hasPublicationYear "2005" @default.
• W2102392020 type Work @default.
• W2102392020 sameAs 2102392020 @default.
• W2102392020 citedByCount "132" @default.
• W2102392020 countsByYear W21023920202012 @default.
• W2102392020 countsByYear W21023920202013 @default.
• W2102392020 countsByYear W21023920202014 @default.
• W2102392020 countsByYear W21023920202015 @default.
• W2102392020 countsByYear W21023920202016 @default.
• W2102392020 countsByYear W21023920202017 @default.
• W2102392020 countsByYear W21023920202018 @default.
• W2102392020 countsByYear W21023920202019 @default.
• W2102392020 countsByYear W21023920202021 @default.
• W2102392020 countsByYear W21023920202022 @default.
• W2102392020 countsByYear W21023920202023 @default.
• W2102392020 crossrefType "journal-article" @default.
• W2102392020 hasAuthorship W2102392020A5020653419 @default.
• W2102392020 hasAuthorship W2102392020A5024174638 @default.
• W2102392020 hasAuthorship W2102392020A5025585163 @default.
• W2102392020 hasAuthorship W2102392020A5029344208 @default.
• W2102392020 hasAuthorship W2102392020A5049570974 @default.
• W2102392020 hasAuthorship W2102392020A5051414786 @default.
• W2102392020 hasAuthorship W2102392020A5052081598 @default.
• W2102392020 hasAuthorship W2102392020A5071250790 @default.
• W2102392020 hasAuthorship W2102392020A5076700157 @default.
• W2102392020 hasAuthorship W2102392020A5082442667 @default.
• W2102392020 hasAuthorship W2102392020A5089405869 @default.
• W2102392020 hasConcept C121608353 @default.
• W2102392020 hasConcept C126322002 @default.
• W2102392020 hasConcept C141071460 @default.
• W2102392020 hasConcept C142724271 @default.
• W2102392020 hasConcept C170493617 @default.
• W2102392020 hasConcept C2776033226 @default.
• W2102392020 hasConcept C2777783956 @default.
• W2102392020 hasConcept C2779013556 @default.

• next